Novel and existing flexible survival methods for network meta-analyses - Supplementary materials
Figure 1. A) Overall survival hazard plots in evidence network for the pooled Checkmate 017-057 trials comparing nivolumab with docetaxel. B) Keynote 010 trial comparing pembrolizumab with docetaxel, C) POPLAR trial comparing atezolizumab with docetaxel, D) OAK trial comparing atezolizumab with docetaxel
Figure 2. Network of evidence
Figure 3. Log cumulative hazard plots and Schoenfeld plots for A) pooled checkmate 017 and 057 trials, Keynote 010; C) POPLAR D) OAK
Figure 4 Predicted survival best fitting reduced models and corresponding 95% credible interval on therapy with longest predicted survival; A) loglogistic standard parametric, B) loglogistic piecewise, C) loglogistic spline, D) Loglogistic non-mixture cure, E) loglogistic mixture cure and F) Weibull mixture, G) second order Fractional polynomial.
Table 1 Overview of the percentiles related to placements of knots and the corresponding uncensored survival times in the considered NMA dataset.
Table 2. LOOICs of fully specified (treatment effects on all parameters) survival network meta-analysis